Indian Diabetes Market Research and Analysis, 2015-2022
MARKET INSIGHTS
The Indian diabetes market is estimated to grow with the CAGR of 20.5% during the period 2017-2022. The major factors that are augmenting the growth of the market are increase in the geriatric population of the India, urbanization and increasing prevalence of diabetes in the country. Additionally, rising obesity levels, innovation and development of new product for the diagnosis and treatment of diabetes and growing trend of the wearable devices and POC solution are also some of the major factors that are fuelling the growth of the Indian diabetes market.
India has huge potential for the growth of the diabetes market. Diabetes is an expensive and rapidly growing health problem all over the world. In 2015, it is estimated that the approximately 370 million across the globe have diabetes, out of which more than 90% of the population have Type-II diabetes. India has the second largest number of diabetic’s population in the world. In 2015, about 60 million people India is suffering from diabetes. Moreover, 75 million people are in the risk to develop diabetes. These are the major factors that are attracting multinational companies to invest in India. Therefore increasing investment by the key players in the India are driving the growth of the diabetes market.
Increasing geriatric population is also one of the major factors driving the growth of the diabetes market in India. In the year 2015, population aging 65 year or older is estimated to account for about 6% of the total population of the India i.e. 78 million, it is further estimated to reach 8.8% by the year 2030. Population aging 65 or older are more prone to diabetes. Therefore increasing geriatric population in India is estimated to motivate the growth of the diabetes market in India.
However, there are certain factors that are affecting the growth of the diabetes market in India. Lack of awareness among people, high cost and recurring cost of treatment, lack of availability of insulin pumps and CGMS devices are some of the major constraints that are hindering the growth of the diabetes market in the region.
COMPETITIVE INSIGHTS
Key players of the Indian diabetes market are AstraZeneca Pharma India ltd, Eli Lily and company India ltd, GlaxoSmithKline Pharmaceuticals ltd, Glenmark Pharmaceuticals, Lupin pharmaceuticals ltd, Merck & co, Micro labs Ltd, MSD pharmaceuticals, Novartis India, Novo Nordisk India, Pfizer India, Sanofi Aventis, Sun Pharmaceuticals, USV India.
Market Segments
1. INDIAN DIABETES MARKET BY TYPE
2. INDIAN DIABETES MARKET BY DRUG CLASS
3. INDIAN DIABETES MARKET BY DEVICES
OMR REPORT COVERS:
The Indian diabetes market is estimated to grow with the CAGR of 20.5% during the period 2017-2022. The major factors that are augmenting the growth of the market are increase in the geriatric population of the India, urbanization and increasing prevalence of diabetes in the country. Additionally, rising obesity levels, innovation and development of new product for the diagnosis and treatment of diabetes and growing trend of the wearable devices and POC solution are also some of the major factors that are fuelling the growth of the Indian diabetes market.
India has huge potential for the growth of the diabetes market. Diabetes is an expensive and rapidly growing health problem all over the world. In 2015, it is estimated that the approximately 370 million across the globe have diabetes, out of which more than 90% of the population have Type-II diabetes. India has the second largest number of diabetic’s population in the world. In 2015, about 60 million people India is suffering from diabetes. Moreover, 75 million people are in the risk to develop diabetes. These are the major factors that are attracting multinational companies to invest in India. Therefore increasing investment by the key players in the India are driving the growth of the diabetes market.
Increasing geriatric population is also one of the major factors driving the growth of the diabetes market in India. In the year 2015, population aging 65 year or older is estimated to account for about 6% of the total population of the India i.e. 78 million, it is further estimated to reach 8.8% by the year 2030. Population aging 65 or older are more prone to diabetes. Therefore increasing geriatric population in India is estimated to motivate the growth of the diabetes market in India.
However, there are certain factors that are affecting the growth of the diabetes market in India. Lack of awareness among people, high cost and recurring cost of treatment, lack of availability of insulin pumps and CGMS devices are some of the major constraints that are hindering the growth of the diabetes market in the region.
COMPETITIVE INSIGHTS
Key players of the Indian diabetes market are AstraZeneca Pharma India ltd, Eli Lily and company India ltd, GlaxoSmithKline Pharmaceuticals ltd, Glenmark Pharmaceuticals, Lupin pharmaceuticals ltd, Merck & co, Micro labs Ltd, MSD pharmaceuticals, Novartis India, Novo Nordisk India, Pfizer India, Sanofi Aventis, Sun Pharmaceuticals, USV India.
Market Segments
1. INDIAN DIABETES MARKET BY TYPE
2. INDIAN DIABETES MARKET BY DRUG CLASS
3. INDIAN DIABETES MARKET BY DEVICES
OMR REPORT COVERS:
- Comprehensive research methodology of Global Indian Diabetes Market
- This report also includes detailed and extensive market overview with Analyst insights & key market trends.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Indian Diabetes Market
- Insights about market determinants which are stimulating the Global Indian Diabetes Market
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASE IN GERIATRIC POPULATION
3.1.2. RISING OBESITY LEVELS
3.1.3. URBANIZATION
3.1.4. INCREASING PREVALENCE OF DIABETES IN INDIA
3.1.5. INNOVATION AND DEVELOPMENT OF NEW PRODUCTS
3.1.6. GROWING POPULARITY OF WEARABLE DEVICES AND POC SOLUTIONS
3.2. RESTRAINTS
3.2.1. HIGH AND RECURRING COST OF TREATMENT
3.2.2. LACK OF AWARENESS AMONG PEOPLE
3.2.3. LACK OF AVAILABILITY OF INSULIN PUMPS AND CGMS DEVICES
3.3. OPPORTUNITIES
3.3.1. INCREASING INVESTMENT BY MARKET PLAYERS IN INDIA
3.3.2. DEVELOPMENT OF ARTIFICIAL PANCREASES
3.3.3. DEVELOPMENT OF MINIMALLY INVASIVE AND NON INVASIVE MONITORING DEVICES
4. MARKET SEGMENTATION
4.1. INDIAN DIABETES MARKET BY TYPE
4.1.1. TYPE 1 DIABETES MARKET
4.1.2. TYPE 2 DIABETES MARKET
4.1.3. GESTATIONAL
4.2. INDIAN DIABETES MARKET BY DRUG CLASS
4.2.1. ALPHA-GLUCOSIDASE INHIBITORS
4.2.2. AMYLIN ANALOGS
4.2.3. ANTIDIABETIC COMBINATIONS
4.2.4. DIPEPTIDYL PEPTIDASE 4 INHIBITORS
4.2.5. INCRETIN MIMETICS
4.2.6. INSULIN
4.2.7. MEGLITINIDES
4.2.8. NON-SULFONYLUREAS
4.2.9. SGLT-2 INHIBITORS
4.2.10. SULFONYLUREAS
4.2.11. THIAZOLIDINEDIONES
4.3. INDIAN DIABETES MARKET BY DEVICES
4.3.1. BLOOD GLUCOSE METERS
4.3.2. BLOOD GLUCOSE STRIPS
4.3.3. INSULIN INJECTION PENS
4.3.4. INSULIN SYRINGES
4.3.5. CONTINUOUS GLUCOSE MONITORING SYSTEMS
4.3.6. INSULIN PUMPS
4.3.7. LANCETS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGY ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. COMPANY PROFILES
7.1. ASTRAZENECA PHARMA INDIA LTD
7.1.1. INTRODUCTION
7.1.2. ASTRAZENECA PHARMA INDIA LTD PRODUCT PORTFOLIO
7.1.3. ASTRAZENECA PHARMA INDIA LTD RECENT ACTIVITIES
7.2. ELI LILY AND COMPANY INDIA LTD
7.2.1. INTRODUCTION
7.2.2. ELI LILY AND COMPANY INDIA LTD. PRODUCT PORTFOLIO
7.2.3. ELI LILY AND COMPANY INDIA LTD. RECENT ACTIVITIES
7.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD
7.3.1. INTRODUCTION
7.3.2. GLAXOSMITHKLINE PHARMACEUTICALS LTD PRODUCT PORTFOLIO
7.3.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD RECENT ACTIVITIES
7.4. GLENMARK INDIA
7.4.1. INTRODUCTION
7.4.2. GLENMARK INDIA PRODUCT PORTFOLIO
7.4.3. GLENMARK INDIA RECENT ACTIVITIES
7.5. LUPIN PHARMACEUTICALS LTD
7.5.1. INTRODUCTION
7.5.2. LUPIN PHARMACEUTICALS LTD PRODUCT PORTFOLIO
7.5.3. LUPIN PHARMACEUTICALS LTD RECENT ACTIVITIES
7.6. MERCK & CO.
7.6.1. INTRODUCTION
7.6.2. MERCK & CO. PRODUCT PORTFOLIO
7.6.3. MERCK & CO. RECENT ACTIVITIES
7.7. MICRO LABS LTD
7.7.1. INTRODUCTION
7.7.2. MICRO LABS LTD PRODUCT PORTFOLIO
7.7.3. MICRO LABS LTD RECENT ACTIVITIES
7.8. MSD PHARMACEUTICALS
7.8.1. INTRODUCTION
7.8.2. MSD PHARMACEUTICALS PRODUCT PORTFOLIO
7.8.3. MSD PHARMACEUTICALS RECENT ACTIVITIES
7.9. NOVARTIS
7.9.1. INTRODUCTION
7.9.2. NOVARTIS PRODUCT PORTFOLIO
7.9.3. NOVARTIS RECENT ACTIVITIES
7.10. NOVO NORDISK INDIA
7.10.1. INTRODUCTION
7.10.2. NOVO NORDISK INDIA PRODUCT PORTFOLIO
7.10.3. NOVO NORDISK INDIA RECENT ACTIVITIES
7.11. PFIZER INDIA
7.11.1. INTRODUCTION
7.11.2. PFIZER INDIA PRODUCT PORTFOLIO
7.11.3. PFIZER INDIA RECENT ACTIVITIES
7.12. SANOFI INDIA
7.12.1. INTRODUCTION
7.12.2. SANOFI INDIA PRODUCT PORTFOLIO
7.12.3. SANOFI INDIA RECENT ACTIVITIES
7.13. SUN PHARMACEUTICALS INDUSTRIES LTD
7.13.1. INTRODUCTION
7.13.2. SUN PHARMACEUTICALS INDUSTRIES LTD PRODUCT PORTFOLIO
7.13.3. SUN PHARMACEUTICALS INDUSTRIES LTD RECENT ACTIVITIES
7.14. USV INDIA
7.14.1. INTRODUCTION
7.14.2. USV INDIA PRODUCT PORTFOLIO
7.14.3. USV INDIA RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASE IN GERIATRIC POPULATION
3.1.2. RISING OBESITY LEVELS
3.1.3. URBANIZATION
3.1.4. INCREASING PREVALENCE OF DIABETES IN INDIA
3.1.5. INNOVATION AND DEVELOPMENT OF NEW PRODUCTS
3.1.6. GROWING POPULARITY OF WEARABLE DEVICES AND POC SOLUTIONS
3.2. RESTRAINTS
3.2.1. HIGH AND RECURRING COST OF TREATMENT
3.2.2. LACK OF AWARENESS AMONG PEOPLE
3.2.3. LACK OF AVAILABILITY OF INSULIN PUMPS AND CGMS DEVICES
3.3. OPPORTUNITIES
3.3.1. INCREASING INVESTMENT BY MARKET PLAYERS IN INDIA
3.3.2. DEVELOPMENT OF ARTIFICIAL PANCREASES
3.3.3. DEVELOPMENT OF MINIMALLY INVASIVE AND NON INVASIVE MONITORING DEVICES
4. MARKET SEGMENTATION
4.1. INDIAN DIABETES MARKET BY TYPE
4.1.1. TYPE 1 DIABETES MARKET
4.1.2. TYPE 2 DIABETES MARKET
4.1.3. GESTATIONAL
4.2. INDIAN DIABETES MARKET BY DRUG CLASS
4.2.1. ALPHA-GLUCOSIDASE INHIBITORS
4.2.2. AMYLIN ANALOGS
4.2.3. ANTIDIABETIC COMBINATIONS
4.2.4. DIPEPTIDYL PEPTIDASE 4 INHIBITORS
4.2.5. INCRETIN MIMETICS
4.2.6. INSULIN
4.2.7. MEGLITINIDES
4.2.8. NON-SULFONYLUREAS
4.2.9. SGLT-2 INHIBITORS
4.2.10. SULFONYLUREAS
4.2.11. THIAZOLIDINEDIONES
4.3. INDIAN DIABETES MARKET BY DEVICES
4.3.1. BLOOD GLUCOSE METERS
4.3.2. BLOOD GLUCOSE STRIPS
4.3.3. INSULIN INJECTION PENS
4.3.4. INSULIN SYRINGES
4.3.5. CONTINUOUS GLUCOSE MONITORING SYSTEMS
4.3.6. INSULIN PUMPS
4.3.7. LANCETS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGY ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. COMPANY PROFILES
7.1. ASTRAZENECA PHARMA INDIA LTD
7.1.1. INTRODUCTION
7.1.2. ASTRAZENECA PHARMA INDIA LTD PRODUCT PORTFOLIO
7.1.3. ASTRAZENECA PHARMA INDIA LTD RECENT ACTIVITIES
7.2. ELI LILY AND COMPANY INDIA LTD
7.2.1. INTRODUCTION
7.2.2. ELI LILY AND COMPANY INDIA LTD. PRODUCT PORTFOLIO
7.2.3. ELI LILY AND COMPANY INDIA LTD. RECENT ACTIVITIES
7.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD
7.3.1. INTRODUCTION
7.3.2. GLAXOSMITHKLINE PHARMACEUTICALS LTD PRODUCT PORTFOLIO
7.3.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD RECENT ACTIVITIES
7.4. GLENMARK INDIA
7.4.1. INTRODUCTION
7.4.2. GLENMARK INDIA PRODUCT PORTFOLIO
7.4.3. GLENMARK INDIA RECENT ACTIVITIES
7.5. LUPIN PHARMACEUTICALS LTD
7.5.1. INTRODUCTION
7.5.2. LUPIN PHARMACEUTICALS LTD PRODUCT PORTFOLIO
7.5.3. LUPIN PHARMACEUTICALS LTD RECENT ACTIVITIES
7.6. MERCK & CO.
7.6.1. INTRODUCTION
7.6.2. MERCK & CO. PRODUCT PORTFOLIO
7.6.3. MERCK & CO. RECENT ACTIVITIES
7.7. MICRO LABS LTD
7.7.1. INTRODUCTION
7.7.2. MICRO LABS LTD PRODUCT PORTFOLIO
7.7.3. MICRO LABS LTD RECENT ACTIVITIES
7.8. MSD PHARMACEUTICALS
7.8.1. INTRODUCTION
7.8.2. MSD PHARMACEUTICALS PRODUCT PORTFOLIO
7.8.3. MSD PHARMACEUTICALS RECENT ACTIVITIES
7.9. NOVARTIS
7.9.1. INTRODUCTION
7.9.2. NOVARTIS PRODUCT PORTFOLIO
7.9.3. NOVARTIS RECENT ACTIVITIES
7.10. NOVO NORDISK INDIA
7.10.1. INTRODUCTION
7.10.2. NOVO NORDISK INDIA PRODUCT PORTFOLIO
7.10.3. NOVO NORDISK INDIA RECENT ACTIVITIES
7.11. PFIZER INDIA
7.11.1. INTRODUCTION
7.11.2. PFIZER INDIA PRODUCT PORTFOLIO
7.11.3. PFIZER INDIA RECENT ACTIVITIES
7.12. SANOFI INDIA
7.12.1. INTRODUCTION
7.12.2. SANOFI INDIA PRODUCT PORTFOLIO
7.12.3. SANOFI INDIA RECENT ACTIVITIES
7.13. SUN PHARMACEUTICALS INDUSTRIES LTD
7.13.1. INTRODUCTION
7.13.2. SUN PHARMACEUTICALS INDUSTRIES LTD PRODUCT PORTFOLIO
7.13.3. SUN PHARMACEUTICALS INDUSTRIES LTD RECENT ACTIVITIES
7.14. USV INDIA
7.14.1. INTRODUCTION
7.14.2. USV INDIA PRODUCT PORTFOLIO
7.14.3. USV INDIA RECENT ACTIVITIES
LIST OF TABLES
TABLE #1 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY TYPE 2015-2022 ($ MILLION)
TABLE #2 INDIAN TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #3 INDIAN TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #4 INDIAN GESTATIONAL MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #5 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DRUG CLASS, 2015-2022 ($ MILLION)
TABLE #6 INDIAN ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #7 INDIAN AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #8 INDIAN ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #9 INDIAN DIPEPTIDYL PEPTIDASE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #10 INDIAN INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #11 INDIAN INSULIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #12 INDIAN MEGLITINIDES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #13 INDIAN NON SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #14 INDIAN THIAZOLIDINEDIONES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #15 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DEVICES, 2015-2022 ($ MILLION)
TABLE #16 INDIAN BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #17 INDIAN BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #18 INDIAN INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #19 INDIAN INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, BY CONNECTOR, 2015-2022 ($ MILLION)
TABLE #20 INDIAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #21 INDIAN INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #22 INDIAN LANCETS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #23 ASTRAZENECA PHARMA INDIA LTD PRODUCT PORTFOLIO
TABLE #24 ASTRAZENECA PHARMA INDIA LTD RECENT ACTIVITIES
TABLE #25 ELI LILY AND COMPANY INDIA LTD. PRODUCT PORTFOLIO
TABLE #26 ELI LILY AND COMPANY INDIA LTD. RECENT ACTIVITIES
TABLE #27 GLAXOSMITHKLINE PHARMACEUTICALS LTD PRODUCT PORTFOLIO
TABLE #28 GLAXOSMITHKLINE PHARMACEUTICALS LTD RECENT ACTIVITIES
TABLE #29 GLENMARK INDIA PRODUCT PORTFOLIO
TABLE #30 GLENMARK INDIA RECENT ACTIVITIES
TABLE #31 LUPIN PHARMACEUTICALS LTD PRODUCT PORTFOLIO
TABLE #32 LUPIN PHARMACEUTICALS LTD RECENT ACTIVITIES
TABLE #33 MERCK & CO. PRODUCT PORTFOLIO
TABLE #34 MERCK & CO. RECENT ACTIVITIES
TABLE #35 MICRO LABS LTD PRODUCT PORTFOLIO
TABLE #36 MICRO LABS LTD RECENT ACTIVITIES
TABLE #37 MSD PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #38 MSD PHARMACEUTICALS RECENT ACTIVITIES
TABLE #39 NOVARTIS PRODUCT PORTFOLIO
TABLE #40 NOVARTIS RECENT ACTIVITIES
TABLE #41 NOVO NORDISK INDIA PRODUCT PORTFOLIO
TABLE #42 NOVO NORDISK INDIA RECENT ACTIVITIES
TABLE #43 PFIZER INDIA PRODUCT PORTFOLIO
TABLE #44 PFIZER INDIA RECENT ACTIVITIES
TABLE #45 SANOFI INDIA PRODUCT PORTFOLIO
TABLE #46 SANOFI INDIA RECENT ACTIVITIES
TABLE #47 SUN PHARMACEUTICALS INDUSTRIES LTD PRODUCT PORTFOLIO
TABLE #48 SUN PHARMACEUTICALS INDUSTRIES LTD RECENT ACTIVITIES
TABLE #49 USV INDIA PRODUCT PORTFOLIO
TABLE #50 USV INDIA RECENT ACTIVITIES
TABLE #1 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY TYPE 2015-2022 ($ MILLION)
TABLE #2 INDIAN TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #3 INDIAN TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #4 INDIAN GESTATIONAL MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #5 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DRUG CLASS, 2015-2022 ($ MILLION)
TABLE #6 INDIAN ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #7 INDIAN AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #8 INDIAN ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #9 INDIAN DIPEPTIDYL PEPTIDASE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #10 INDIAN INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #11 INDIAN INSULIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #12 INDIAN MEGLITINIDES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #13 INDIAN NON SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #14 INDIAN THIAZOLIDINEDIONES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #15 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DEVICES, 2015-2022 ($ MILLION)
TABLE #16 INDIAN BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #17 INDIAN BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #18 INDIAN INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #19 INDIAN INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, BY CONNECTOR, 2015-2022 ($ MILLION)
TABLE #20 INDIAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #21 INDIAN INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #22 INDIAN LANCETS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #23 ASTRAZENECA PHARMA INDIA LTD PRODUCT PORTFOLIO
TABLE #24 ASTRAZENECA PHARMA INDIA LTD RECENT ACTIVITIES
TABLE #25 ELI LILY AND COMPANY INDIA LTD. PRODUCT PORTFOLIO
TABLE #26 ELI LILY AND COMPANY INDIA LTD. RECENT ACTIVITIES
TABLE #27 GLAXOSMITHKLINE PHARMACEUTICALS LTD PRODUCT PORTFOLIO
TABLE #28 GLAXOSMITHKLINE PHARMACEUTICALS LTD RECENT ACTIVITIES
TABLE #29 GLENMARK INDIA PRODUCT PORTFOLIO
TABLE #30 GLENMARK INDIA RECENT ACTIVITIES
TABLE #31 LUPIN PHARMACEUTICALS LTD PRODUCT PORTFOLIO
TABLE #32 LUPIN PHARMACEUTICALS LTD RECENT ACTIVITIES
TABLE #33 MERCK & CO. PRODUCT PORTFOLIO
TABLE #34 MERCK & CO. RECENT ACTIVITIES
TABLE #35 MICRO LABS LTD PRODUCT PORTFOLIO
TABLE #36 MICRO LABS LTD RECENT ACTIVITIES
TABLE #37 MSD PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #38 MSD PHARMACEUTICALS RECENT ACTIVITIES
TABLE #39 NOVARTIS PRODUCT PORTFOLIO
TABLE #40 NOVARTIS RECENT ACTIVITIES
TABLE #41 NOVO NORDISK INDIA PRODUCT PORTFOLIO
TABLE #42 NOVO NORDISK INDIA RECENT ACTIVITIES
TABLE #43 PFIZER INDIA PRODUCT PORTFOLIO
TABLE #44 PFIZER INDIA RECENT ACTIVITIES
TABLE #45 SANOFI INDIA PRODUCT PORTFOLIO
TABLE #46 SANOFI INDIA RECENT ACTIVITIES
TABLE #47 SUN PHARMACEUTICALS INDUSTRIES LTD PRODUCT PORTFOLIO
TABLE #48 SUN PHARMACEUTICALS INDUSTRIES LTD RECENT ACTIVITIES
TABLE #49 USV INDIA PRODUCT PORTFOLIO
TABLE #50 USV INDIA RECENT ACTIVITIES
LIST OF FIGURES
FIGURE #1 INDIAN DIABETES PREVALANCE RATE, 2010-2015
FIGURE #2 INDIAN TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
FIGURE #3 INDIAN TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
FIGURE #4 INDIAN GESTATIONAL MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
FIGURE #5 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DRUG CLASS, 2015-2022 ($ MILLION)
FIGURE #6 INDIAN ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
COMPANIES MENTIONED
1. Astrazeneca pharma india ltd.
2. Eli Lily and company India ltd.
3. GlaxosmithKline pharmaceuticals ltd.
4. Glenmark pharmaceuticals
5. Lupin pharmaceuticals ltd.
6. Merck & co.
7. Micro labs Ltd.
8. MSD pharmaceuticals
9. Novartis India
10. Novo Nordisk India
11. Pfizer India
12. Sanofi Aventis
13. Sun Pharmaceuticals
14. USV India
FIGURE #1 INDIAN DIABETES PREVALANCE RATE, 2010-2015
FIGURE #2 INDIAN TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
FIGURE #3 INDIAN TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
FIGURE #4 INDIAN GESTATIONAL MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
FIGURE #5 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DRUG CLASS, 2015-2022 ($ MILLION)
FIGURE #6 INDIAN ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
COMPANIES MENTIONED
1. Astrazeneca pharma india ltd.
2. Eli Lily and company India ltd.
3. GlaxosmithKline pharmaceuticals ltd.
4. Glenmark pharmaceuticals
5. Lupin pharmaceuticals ltd.
6. Merck & co.
7. Micro labs Ltd.
8. MSD pharmaceuticals
9. Novartis India
10. Novo Nordisk India
11. Pfizer India
12. Sanofi Aventis
13. Sun Pharmaceuticals
14. USV India
